Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Endogenous hydrogen sulfide (HS)-responsive theranostic agents have attracted extensive attention due to their specificity for colon cancer. However, the development of such agents with high enrichment in tumors and excellent photothermal performance remains challenging.
Results: We prepared hyaluronic acid (HA)-coated Bi-doped cuprous oxide (Bi:CuO@HA) via a one-pot method. The HA specifically targets colon cancer tumor cells to improve the enrichment of Bi:CuO@HA at tumor sites, while the doped Bi both enhances the photothermal performance of the HS-triggered CuO and serves as an agent for tumor imaging. The results in this work demonstrated that the Bi:CuO@HA nanoparticles exhibit good biocompatibility, target colon cancer tumor cells, facilitate computed tomography imaging, and enhanced HS-responsive photothermal therapy performance, resulting in an excellent therapeutic effect in colon cancer.
Conclusions: The novel Bi:CuO@HA nanoparticles exhibit excellent tumor targeting and photothermal therapeutic effects, which provide new strategies and insights for colon cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327345 | PMC |
| http://dx.doi.org/10.1186/s12951-022-01555-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence, treatment, and survival of patients with appendiceal adenocarcinomas and low-grade appendiceal mucinous neoplasms: linked Swedish national registry study.
BJS Open
September 2025
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Background: Appendiceal adenocarcinomas and low-grade appendiceal mucinous neoplasms (LAMNs) are rare tumours. Much of the existing knowledge is derived from registry-based studies, particularly the Surveillance, Epidemiology, and End Results database in the USA.
Methods: This retrospective cohort study used data from the Swedish Cancer Registry, Swedish Cause of Death Registry, and the National Patient Registry to analyse demographic characteristics and outcomes of patients diagnosed with appendiceal adenocarcinoma or LAMN between 2005 and 2019.
[Interleukin-6 as a biochemical marker of intestinal anastomotic leakage].
Khirurgiia (Mosk)
September 2025
Saint Petersburg State University, Saint Petersburg, Russia.
Objective: To evaluate diagnostic significance of IL-6 compared to CRP for early detection of anastomotic leakage after colon resection for colorectal cancer.
Material And Methods: The study included 277 patients who underwent total resection for colorectal cancer. Patients were retrospectively divided into three groups: without complications (=227), with anastomotic leakage (=30), and other postoperative complications (=20).
Pilot Study: Identification of the T Cell Tumor Microenvironment of Premalignant and Malignant Anal Lesions.
Dis Colon Rectum
September 2025
Department of Surgery, Oregon Health & Science University, Portland, Oregon.
Background: Anal squamous cell cancer incidence has risen 2.2% each year over the past decade. Current screening includes anal cytology and high-resolution anoscopy but is burdened with sampling error and patient discomfort.
View Article and Find Full Text PDFAdjuvant Chemotherapy for Patients With Chronic Kidney Disease: A Study on Treatment Adoption and Associated Factors.
Cancer Med
September 2025
Division of Health Services Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
Introduction: Patients with chronic kidney disease (CKD) face unique challenges in cancer treatment, including the need for chemotherapy dose adjustments and avoiding nephrotoxic agents, often leading to less aggressive treatment. However, little is known about the real-world administration of adjuvant chemotherapy for patients with CKD. In this study, we aimed to investigate the prevalence of adjuvant chemotherapy in patients with CKD and to explore factors influencing chemotherapy use.
View Article and Find Full Text PDFOptimal Extent of Lymph Node Dissection for Non-Metastatic Colon Cancer by Tumor Location: Evaluation of the Therapeutic Value Index for Each Lymph Node Station.
Ann Gastroenterol Surg
September 2025
Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Aims: To determine the optimal extent of lymph node dissection for non-metastatic colon cancer by tumor location based on the therapeutic value index (TVI) for each lymph node station.
Methods: Consecutive patients with surgical stage I-III colon or rectosigmoid cancer in the Japanese Society for Cancer of the Colon and Rectum database who underwent curative resection between January 2003 and December 2014 were analyzed. The TVI was defined as the incidence of lymph node metastasis multiplied by 5-year overall survival and calculated for each nodal station stratified by tumor location.